Relevant bibliographies by topics / Ciclopiroxolamine / Journal articles
To see the other types of publications on this topic, follow the link: Ciclopiroxolamine.

Journal articles on the topic 'Ciclopiroxolamine'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 40 journal articles for your research on the topic 'Ciclopiroxolamine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Holešová, Sylva, Jana Kupková, Michal Ritz, and Erich Pazdziora. "Antimicrobial ciclopiroxolamine/clay nanocomposites." Materials Today: Proceedings 5 (2018): S20—S28. http://dx.doi.org/10.1016/j.matpr.2018.05.053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Szepes, Eva, and I. Schneider. "Zur Behandlung yon Dermatomykosen mit Ciclopiroxolamine/Ciclopiroxolamine in the Treatment of Dermatomycoses." Mycoses 29, no. 8 (April 24, 2009): 382–86. http://dx.doi.org/10.1111/j.1439-0507.1986.tb03806.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Romano, C., A. Ghilardi, D. Calo, and E. Maritati. "Contact dermatitis due to ciclopiroxolamine." Mycoses 49, no. 4 (July 2006): 338–39. http://dx.doi.org/10.1111/j.1439-0507.2006.01245.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schaller, Martin, Nikola Krnjaic, Markus Niewerth, Gerald Hamm, Bernhard Hube, and Hans C. Korting. "Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans." Journal of Medical Microbiology 52, no. 3 (March 1, 2003): 247–49. http://dx.doi.org/10.1099/jmm.0.05048-0.

Full text
Abstract:
The inhibitory effect of human immunodeficiency virus (HIV) proteinase inhibitors amprenavir and saquinavir and antifungal agents terbinafine, ketoconazole, amphotericin B and ciclopiroxolamine on aspartyl proteinases (Saps) secreted by Candida albicans was tested in an in vitro spectophotometric assay. As expected, both HIV proteinase inhibitors showed a significant inhibitory effect on Sap activity, which was comparable to that of the classical aspartyl proteinase inhibitor pepstatin A (P < 0.001). Antifungal drugs such as ketoconazole, terbinafine and amphotericin B had no, or only minor, inhibitory effects on proteolytic activity. In contrast, a significant reduction in Sap activity could be demonstrated during treatment with the antifungal agent ciclopiroxolamine (P < 0.001). These results point to a multiple effect of this antimycotic agent and might explain the reduced adherence of C. albicans to human epithelial cells at subinhibitory doses.
APA, Harvard, Vancouver, ISO, and other styles
5

Schmidt-Wolf, Ingo, Nkem Purity C. Emekwue, and Hans Weiher. "Ethacrynic Acid and Ciclopiroxolamine in Various Cancer Cells." International Journal of Hematology and Therapy 4, no. 1 (March 26, 2018): 16–24. http://dx.doi.org/10.15436/2381-1404.18.1666.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Unholzer, A., S. Schinzel, K. H. Nietsch, G. E. Jung, and Hans Christian Korting. "Ciclopiroxolamine Cream 1% in the Treatment of Seborrhoeic Dermatitis." Clinical Drug Investigation 22, no. 3 (2002): 167–72. http://dx.doi.org/10.2165/00044011-200222030-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Carrillo-Muñoz, A. J., S. Brió, R. Alonso, O. del Valle, P. Santos, and G. Quindós. "Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates." International Journal of Antimicrobial Agents 20, no. 5 (November 2002): 375–79. http://dx.doi.org/10.1016/s0924-8579(02)00206-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tietz, Hans-Jürgen. "Treatment of chronic vulvovaginal candidiasis with posaconazole and ciclopiroxolamine." Health 02, no. 06 (2010): 513–18. http://dx.doi.org/10.4236/health.2010.26077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gasparini, G., D. Contini, A. Torti, C. Guidarelli, A. Lasagni, and R. Caputo. "The Effect of Ciclopiroxolamine Investigated by Means of the Freeze-Fracture Technique: Untersuchung der Wirkung von Ciclopiroxolamin mit der Freeze-Fracture-Technik." Mycoses 29, no. 11 (April 24, 2009): 539–44. http://dx.doi.org/10.1111/j.1439-0507.1986.tb03956.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Y. C., M. T. Chuan, and Y. C. Lü. "Efficacy of ciclopiroxolamine 1% cream in onychomycosis and tinea pedis." Mycoses 34, no. 1-2 (April 24, 2009): 93–95. http://dx.doi.org/10.1111/j.1439-0507.1991.tb00625.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Hänel, H., B. Abrams, W. Dittmar, and G. Ehlers. "A Comparison of Bifonazole and Ciclopiroxolamine: In Vitro, Animal, and Clinical Studies./Bifonazol und Ciclopiroxolamin im Vergleich: In vitroStudien, Tierversuche und klinische Untersuchungen." Mycoses 31, no. 12 (April 24, 2009): 632–40. http://dx.doi.org/10.1111/j.1439-0507.1988.tb04418.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

PALACIO-HFRNANZ, A. DEL, J. GUARRO-ARTIGAS, M. J. FIGUERAS-SALVAT, J. ESTEBAN-MORENO, and S. LOPEZ-GOMEZ. "Changes in fungal ultrastructure after short-course ciclopiroxolamine therapy in pityriasis versicolor." Clinical and Experimental Dermatology 15, no. 2 (March 1990): 95–100. http://dx.doi.org/10.1111/j.1365-2230.1990.tb02040.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Unholzer, A., G. Varigos, D. Nicholls, S. Schinzel, K. H. Nietsch, H. Ulbricht, and H. C. Korting. "Ciclopiroxolamine Cream for Treating Seborrheic Dermatitis: A Double-Blind Parallel Group Comparison." Infection 30, no. 6 (December 1, 2002): 373–76. http://dx.doi.org/10.1007/s15010-002-2196-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Ceschin-Roques, C. G., H. Hänel, S. M. Pruja-Bougaret, I. Lagarde, J. Vandermander, and G. Michel. "Ciclopiroxolamine Cream 1%: In vitro and in vivo Penetration into the Stratum corneum." Skin Pharmacology and Physiology 4, no. 2 (1991): 95–99. http://dx.doi.org/10.1159/000210930.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Cisło, M. "Efficacy of batrafen (ciclopiroxolamine) in treatment of dermatomycose. An open multicenter study, Poland." Journal of the European Academy of Dermatology and Venereology 5, no. 1 (October 1995): S94. http://dx.doi.org/10.1016/0926-9959(95)96128-u.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Schaller, Martin, Claudia Borelli, Ursula Berger, Birgit Walker, Sybille Schmidt, Günther Weindl, and Andreas Jäckel. "Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine againstTrichophyton rubrumin anin vitromodel of dermatophyte nail infection." Medical Mycology 47, no. 7 (November 3, 2009): 753–58. http://dx.doi.org/10.3109/13693780802577892.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Belliardo, Flavio, Antonella Bertolino, Giancarlo Brandolo, and Claudio Lucarelli. "Micro-liquid chromatography method for the determination of ciclopiroxolamine after pre-column derivatization in topical formulations." Journal of Chromatography A 553 (August 1991): 41–45. http://dx.doi.org/10.1016/s0021-9673(01)88470-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Mayser, Peter, Jörg Kupfer, Diana Nemetz, Ute Schäfer, Martin Nilles, Wiebke Hort, and Uwe Gieler. "Treatment of Head and Neck Dermatitis with Ciclopiroxolamine Cream – Results of a Double-Blind, Placebo-Controlled Study." Skin Pharmacology and Physiology 19, no. 3 (2006): 153–58. http://dx.doi.org/10.1159/000092596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Nakashima, T., E. Sato, Y. Niwano, M. Kohno, W. Muraoka, and T. Oda. "Inhibitory or scavenging action of ketoconazole and ciclopiroxolamine against reactive oxygen species released by primed inflammatory cells." British Journal of Dermatology 156, no. 4 (April 2007): 720–27. http://dx.doi.org/10.1111/j.1365-2133.2006.07655.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Dupuy, P., C. Maurette, J. C. Amoric, and O. Chosidow. "Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis." British Journal of Dermatology 144, no. 5 (May 2001): 1033–37. http://dx.doi.org/10.1046/j.1365-2133.2001.04194.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Gehse, M., S. Küster, and M. Gloor. "Über die effektive Hornschichthemmtiefe von Ciclopiroxolamin und Naftifin in Abhängigkeit von der galenischen Zubereitung. On the Effective Dimension of Inhibition of Ciclopiroxolamine and Naftifine in the Horny Layer with Regard to the Galenic Preparatio." Mycoses 30, no. 7 (April 24, 2009): 322–25. http://dx.doi.org/10.1111/j.1439-0507.1987.tb04397.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

del Palacio, A., M. S. Cuétara, M. J. López-Suso, E. Amor, and M. Garau. "Randomized prospective comparative study: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis." Mycoses 45, no. 7-8 (October 2002): 317–28. http://dx.doi.org/10.1046/j.1439-0507.2002.00737.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Biancalana, Fernanda Simas Corrêa, Luzia Lyra, Maria Luiza Moretti, Katsuhiko Kamei, and Angélica Zaninelli Schreiber. "Standardization of Hyphal Growth Inhibition Rate as a Means of Evaluating Microsporum spp. in vitro Susceptibility to Terbinafine, Griseofulvin, and Ciclopiroxolamine." Mycopathologia 172, no. 4 (May 25, 2011): 279–85. http://dx.doi.org/10.1007/s11046-011-9433-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Chosidow, O., C. Maurette, and P. Dupuy. "Randomized, Open-Labeled, Non-Inferiority Study between Ciclopiroxolamine 1% Cream and Ketoconazole 2% Foaming Gel in Mild to Moderate Facial Seborrheic Dermatitis." Dermatology 206, no. 3 (2003): 233–40. http://dx.doi.org/10.1159/000068904.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Seite, Sophie, André Rougier, and Sergio Talarico. "Randomized study comparing the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis." Journal of Cosmetic Dermatology 8, no. 4 (December 2009): 249–53. http://dx.doi.org/10.1111/j.1473-2165.2009.00460.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Dittmar, W., and N. Jovic̀. "Laboratory Techniques Alternative to In Vivo Experiments for Studying the Liberation, Penetration and Fungicidal Action of Topical Antimycotic Agents in the Skin, Including Ciclopiroxolamine." Mycoses 30, no. 7 (April 24, 2009): 326–42. http://dx.doi.org/10.1111/j.1439-0507.1987.tb04399.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Mohamed, Shaimaa, Amal Awad, Youssef Elsaedy, and Gamal Younis. "Detection of mold species in poultry farms in refer to their virulence potential." Mansoura Veterinary Medical Journal 21, no. 1 (March 31, 2020): 6–13. http://dx.doi.org/10.35943/mvmj.2020.21.102.

Full text
Abstract:
Objective: The aim of the present study was to isolate and identify mold species from poultry farms with detection of their virulence potential, biofilm formation capability and to perform antifungal susceptibility testing to some representative isolates. Design: Observational study. Animals: Fifty freshly dead broiler chicks were included in this study. Procedures: A total of 250 samples were collected from 50 diseased chicks (5 samples each), including lung, liver, kidney, heart, and tracheal swap. In addition, litter samples were collected from 7 poultry farms and were subjected to mycological examination. The isolated mold species have been tested for hemolytic activity, catalase, amylase, lipase, and biofilm production activity; besides, detection of virulence genes (rhbA, fos-1, and pskB) using PCR assay. . Results: A total of 208 mold isolates were identified, with five genera; Aspergillus (84.6%), Zygomycetes (12.9%), Acremonium (0.96%), Penicillium (0.96%) and Alternaria (0.48%). Mold isolates displayed various degrees of fungal activities on blood agar plates, catalase activity, amylase activity, lipase activity, and the ability for biofilm production in vitro. Regarding the selected virulence genes, fos-1 was detected in A.fumigatus (3 isolates) and A.flavus (2isolates). While pksP gene was detected in A.fumigatus (7 isolates) and A.niger (2 isolates) and rhbA detected in A. fumigatus (8 isolates) and one isolate of A. flavus of the total evaluated species. The MIC determination provide evidence for the high resistance of all evaluated isolates to nystatin, and a relatively higher sensitivity was displayed by clotrimazole followed by ciclopiroxolamine and tioconazole. Conclusion and clinical relevance: The results reveal that most of the fungal isolates tested displayed enzymatic activity, which are the most effective virulence factors contributing to fungal pathogenicity and high resistance to antifungal, which represents a potential public health concern.
APA, Harvard, Vancouver, ISO, and other styles
28

Martini, Lorenzo. "A Potent Cocktail of Clotrimazole, Ciclopiroxolamine, Zinc Ion and Tridecyl Salycilate Is Capable To Struggle Radically the Pityriasis Versicolor, Even the Repetitive and the Intermittent Ones." IOSR Journal of Pharmacy and Biological Sciences 11, no. 04 (April 2016): 48–50. http://dx.doi.org/10.9790/3008-1104014850.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Tejedor, I., S. Duvert-Lehembre, M. Beylot-Barry, S. Ly, S. Bechu, J. M. Amici, G. Quereux, et al. "Étude randomisée en double insu comparant le tacrolimus pommade (Protopic©) versus ciclopiroxolamine (crème Mycoster®) dans le traitement d’entretien de la dermatite séborrhéique sévère du visage de l’adulte." Annales de Dermatologie et de Vénéréologie 146, no. 12 (December 2019): A81—A82. http://dx.doi.org/10.1016/j.annder.2019.09.071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Niewerth, M., M. Schaller, H. C. Korting, and B. Hube. "Wirkungsweise von Ciclopiroxolamin auf Candida albicans." Mycoses 45, S1 (September 2002): 63–68. http://dx.doi.org/10.1111/j.1439-0507.2002.tb04549.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Ermosilla, V., G. Lorette, N. Doss, P. Morinet, and V. Sibaud. "P71 - Dermite séborrheique du cuir chevelu : résultats d’une étude clinique comparant un shampooing contenant 1,5 % de ciclopiroxolamine et 1 % de pirythione de zinc à un shampooing contenant 2 % de kétoconazole et à un placebo." Annales de Dermatologie et de Vénéréologie 132 (October 2005): 113–14. http://dx.doi.org/10.1016/s0151-9638(05)79800-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Tietz. "The problem of treating chronic recurrent vaginal mycosis." Therapeutische Umschau 59, no. 9 (September 1, 2002): 481–84. http://dx.doi.org/10.1024/0040-5930.59.9.481.

Full text
Abstract:
Die vulvovaginale Kandidose ist eine der häufigsten Infektionskrankheiten. Die überwiegend akuten Formen treten sporadisch auf, verlaufen unkompliziert und lassen sich therapeutisch weitgehend mit topischen Antimykotika beherrschen. Chronische Infektionen sind indes fast immer ein Therapieproblem. In den meisten Fällen ist eine systemische Therapie indiziert. Hierbei ist aufgrund bestehender Erregerlücken bei Fluconazol und Itraconazol die vorherige Identifizierung der Erregerart obligatorisch. Die Therapie der chronischen Vulvovaginalkandidose schließt ebenso die Identifizierung und Sanierung bestehender endogener (Mundhöhle, Darm) sowie exogener (Sexualpartner) Reinfektionsquellen ein. Vorgeschlagen wird folgende Drei-Säulen-Therapie: (1) orointestinale selektive Pilzdekontamination mit einem Polyenantimykotikum in Abhängigkeit vom Besiedlungsstatus, (2) systemische Therapie mit Fluconazol oder Itraconazol in Abhängigkeit von der Pilzart, (3) topische Therapie unter Anwendung von Ciclopiroxolamin als synergistischem Kombinationspartner.
APA, Harvard, Vancouver, ISO, and other styles
33

Wajnberg, M., and Anafrida Wajnberg. "Doppelblind-Vergleichsstudie mit Ciclopiroxolamin- und Miconazol-Vaginalcreme bei uilvovaginaler Candidose." Mycoses 24, no. 12 (April 24, 2009): 721–30. http://dx.doi.org/10.1111/j.1439-0507.1981.tb01827.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Wohlrab, J., R. H. H. Neubert, E. Sommer, and J. Michael. "Clotrimazol und Ciclopiroxolamin jeweils in Kombination mit Methylprednisolonaceponat in magistralen Rezepturen." Der Hautarzt 68, no. 4 (January 13, 2017): 307–15. http://dx.doi.org/10.1007/s00105-016-3926-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Corte, M., K. Jung, U. Linker, H. Martini, I. Sapp-Boncelet, and H. Schulz. "Topische Anwendung einer 0.1%igen Ciclopiroxolamin-Lösung* zur Behandlung der Pityriasis versicolor." Mycoses 32, no. 4 (April 24, 2009): 200–203. http://dx.doi.org/10.1111/j.1439-0507.1989.tb02232.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Holešová, Sylva, Karla Čech Barabaszová, Marianna Hundáková, Eva Plevová, and Alena Kalendová. "Novel LDPE /vermiculite/ciclopiroxolamine hybrid nanocomposites: Structure, surface properties, and antifungal activity." Journal of Applied Polymer Science, November 5, 2020, 50232. http://dx.doi.org/10.1002/app.50232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Le, Minh Tam, Florian C. Beikert, and Andreas Clad. "A THEORY ON PATHOGENESIS AND NEW APPROACHES IN TREATMENT OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC)." Journal of Medicine and Pharmacy, April 2011, 18–27. http://dx.doi.org/10.34071/jmp.2011.2.2.

Full text
Abstract:
Although as many as 75% women experience at least one episode of VVC during their lifetime and 5-10% will experience RVVC, diagnosis and treatment of RVVC continues to present a challenge. Based on our own theory on pathogenesis with the existing of Candida on vulval keratonizing epithelia proved by our histological findings, we desired to determine the impact of Candida cultures obtained from the external vulva on the diagnosis and the effectiveness of multi-dose of fluconazole in combination with ciclopiroxolamin cream in treatment of RVVC. Among 469 women with recurrent vulvovaginitis who refered to the outpatient clinic of the University Women’s hospital Freiburg, Germany, 156 (33%) women had a positive yeast culture, 120 (77%) of these with positive vulvar swabs. There was a significant association between acute RVVC and pruritus, vulvar erythema, vulvar edema, excoriation and fissure – specific signs of local infection other than contamination (OR were in turn 2,8; 2,4; 3,0; 1,7 and 2,0 times). After 1, 3, 6, 9 and 12 months post-treatment with multi-dose fluconazole in combination with ciclopiroxolamin cream, symptomatic recurrences with positive Candida cultures occurred in 3,6%, 17%, 26%, 32% and 33%, respectively. In conclusion, persisting of Candida in the vulval keratinizing epithelium plays a role in the pathogenesis of RVVC. The treatment regimen with fluconazole 100mg orally per day in 3 weeks in combination with ciclopiroxolamina cream locally shown better long-term cure rates than other current recommended protocols. More controlled randomized trial should be conducted to determined the best doses and regimens.
APA, Harvard, Vancouver, ISO, and other styles
38

Schaller, Martin, Claudia Borelli, Ursula Berger, Birgit Walker, Sybille Schmidt, Gunther Weindl, and Andreas Jackel. "Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection." Medical Mycology, 2009, 1–6. http://dx.doi.org/10.1080/13693780802577892.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Joly, Pascal, Ines Tejedor, Florence Tetart, Hélène Collas Cailleux, Alice Barrel, Paul Arnaud De Preville, Nathalie Mion-Mouton, et al. "Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study." Journal of the American Academy of Dermatology, September 2020. http://dx.doi.org/10.1016/j.jaad.2020.09.055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Paul, C., D. Coustou, M. Lahfa, C. Bulai-Livideanu, N. Doss, I. Mokthar, H. Turki, et al. "A Multicenter, Randomized, Open-Label, Controlled Study Comparing the Efficacy, Safety and Cost-Effectiveness of a Sequential Therapy with RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-Forming Solution with Amorolfine Nail Lacquer Alone in Dermatophytic Onychomycosis." Dermatology, 2013. http://dx.doi.org/10.1159/000353667.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography